Mucormycosis and COVID‐19: An epidemic within a pandemic in India

Mycoses, Journal Year: 2021, Volume and Issue: 64(10), P. 1253 - 1260

Published: July 13, 2021

Coronavirus disease (COVID-19) causes an immunosuppressed state and increases risk of secondary infections like mucormycosis. We evaluated clinical features, predisposing factors, diagnosis outcomes for mucormycosis among patients with COVID-19 infection. This prospective, observational, multi-centre study included 47 consecutive mucormycosis, diagnosed during their course illness, between January 3 March 27, 2021. Data regarding demography, underlying medical conditions, illness treatment were collected. Clinical presentations imaging biochemical characteristics outcome recorded. Of the 2567 admitted to tertiary centres, (1.8%) Mean age was 55 ± 12.8years, majority suffered from diabetes mellitus (n = 36, 76.6%). Most not vaccinated 31, 66.0%) 43, 91.5%) had developed moderate-to-severe pneumonia, while 20 (42.6%) required invasive ventilation. All received corticosteroids broad-spectrum antibiotics most 37, 78.7%) at least one anti-viral medication. time elapsed 12.1 4.6days. Eleven (23.4%) subjects succumbed disease, mostly 8, 72.7%) within 7 days diagnosis. Among who died, 10 (90.9%) pre-existing mellitus, only 2 (18.2%) just vaccine dose all requiring oxygen supplementation mechanical Mucormycosis can occur patients, especially poor glycaemic control, widespread injudicious use antibiotics, Owing high mortality, index suspicion is ensure timely appropriate in high-risk populations.

Language: Английский

---

The current state of laboratory mycology in Asia/Pacific: A survey from the European Confederation of Medical Mycology (ECMM) and International Society for Human and Animal Mycology (ISHAM)

International Journal of Antimicrobial Agents, Journal Year: 2023, Volume and Issue: 61(3), P. 106718 - 106718

Published: Jan. 12, 2023

Invasive fungal infections (IFIs) in Asia/Pacific are a particular threat to patients with malignancies, uncontrolled diabetes mellitus or undiagnosed/untreated human immunodeficiency virus infection and acquired syndrome (HIV/AIDS). Adequate early access diagnostic tools antifungals is essential for IFI clinical management patient survival.Details on institution profile, self-perception IFI, microscopy, culture, serology, antigen detection, molecular testing, therapeutic drug monitoring were collected survey.As of June 2022, 235 centres from 40 countries/territories answered the questionnaire. More than half six countries: India (25%), China (17%), Thailand (5%), Indonesia, Iran, Japan (4% each). Candida spp. (93%) Aspergillus (75%) considered most relevant pathogens. Most institutions had microscopy (98%) culture-based approaches (97%). Furthermore, 79% 66% assays, 63% antibody tests. Access varied between countries/territories. At least one triazole was available 93% reporting sites (voriconazole [89%] common mould-active azole), whereas 80% at amphotericin B formulation, 72% echinocandin.According replies provided, resources diagnosis vary among Economical geographical factors may play key role incidence handling this disease burden. Regional cooperation be good strategy overcome shortcomings.

Language: Английский

---

Definition, diagnosis, and management of COVID-19-associated pulmonary mucormycosis: Delphi consensus statement from the Fungal Infection Study Forum and Academy of Pulmonary Sciences, India

The Lancet Infectious Diseases, Journal Year: 2022, Volume and Issue: 22(9), P. e240 - e253

Published: April 4, 2022

Language: Английский

---

Global Prevalence of COVID-19-Associated Mucormycosis (CAM): Living Systematic Review and Meta-Analysis

Journal of Fungi, Journal Year: 2021, Volume and Issue: 7(11), P. 985 - 985

Published: Nov. 18, 2021

Mucormycosis, a secondary fungal infection, gained much attention in the ongoing COVID-19 pandemic. This deadly infection has high all-cause mortality rate and imposes significant economic, epidemiological, humanistic burden on patients healthcare system. Evidence from published epidemiological studies showed varying prevalence of COVID-19-associated mucormycosis (CAM). study aims to compute pooled CAM other associated clinical outcomes. MEDLINE, Embase, Cochrane Study Register, WHO databases were scanned retrieve relevant articles until August 2021. All reporting among eligible for inclusion. Two investigators independently screened against selection criteria, extracted data, performed quality assessment using JBI tool. The was primary outcome, diabetes, steroid exposure, outcomes interest. Comprehensive Meta-Analysis software version 2 used performing meta-analysis. meta-analysis comprised six with sample size 52,916 mean age 62.12 ± 9.69 years. duration onset 14.59 6.88 days after diagnosis. (seven cases per 1000 patients) 50 times higher than highest recorded background (0.14 patients). A found 29.6% (95% CI: 17.2-45.9%). Optimal glycemic control judicious use steroids should be approach tackling rising cases.

Language: Английский

---

An insight into endophytic antimicrobial compounds: an updated analysis

Plant Biotechnology Reports, Journal Year: 2023, Volume and Issue: 17(4), P. 427 - 457

Published: March 14, 2023

Language: Английский

---

Epidemiology and prognostic factors of mucormycosis in France (2012–2022): a cross-sectional study nested in a prospective surveillance programme

The Lancet Regional Health - Europe, Journal Year: 2024, Volume and Issue: 45, P. 101010 - 101010

Published: Aug. 7, 2024

Language: Английский

---

Results from a national survey on COVID‐19‐associated mucormycosis in Germany: 13 patients from six tertiary hospitals

Mycoses, Journal Year: 2021, Volume and Issue: 65(1), P. 103 - 109

Published: Oct. 20, 2021

Most COVID-19-associated mucormycosis (CAM) cases are reported from India and neighbouring countries. Anecdotally Europe have been presented.To estimate the disease burden describe clinical presentation of CAM in Germany.We identified through German mycology networks scientific societies, collected anonymised information via FungiScope®.We 13 six tertiary referral hospitals diagnosed between March 2020 June 2021. Twelve patients had severe or critical COVID-19, eleven were mechanically ventilated for a median 8 days (range 1-27 days) before diagnosis CAM. Eleven received systemic corticosteroids. Additional underlying medical conditions all but one patient, five immunocompromised because malignancy organ transplantation, three diabetic. developed pneumonia. Mortality was 53.8% with time to death 9 0-214 despite treatment liposomal amphotericin B and/or isavuconazole 10 cases. prevalence amongst hospitalised COVID-19 overall (0.67% 0.58% two centres) those admitted intensive care unit (ICU) (1.47%, 1.78% 0.15% significantly higher compared non-COVID-19 (P < .001 respective comparisons).COVID-19-associated is rare Germany, mostly comorbidities impaired immune system treated ICU high mortality mainly rhino-orbito-cerebral mild India. Risk than other patients.

Language: Английский

---

Evaluation of hospital environment for presence of Mucorales during COVID-19-associated mucormycosis outbreak in India – a multi-centre study

Journal of Hospital Infection, Journal Year: 2022, Volume and Issue: 122, P. 173 - 179

Published: Feb. 3, 2022

Language: Английский

---

Clinical Features and Mortality of COVID-19-Associated Mucormycosis: A Systematic Review and Meta-Analysis

Mycopathologia, Journal Year: 2022, Volume and Issue: 187(2-3), P. 271 - 289

Published: March 21, 2022

Language: Английский

---

Pathogenesis and Pathology of COVID-Associated Mucormycosis: What Is New and Why

Current Fungal Infection Reports, Journal Year: 2022, Volume and Issue: 16(4), P. 206 - 220

Published: Sept. 29, 2022

Language: Английский

---